Royalty pharma plc RPRX 深 滬
等待開盤 09-20 09:30:00 美东时间
27.99
-0.220
-0.78%
華盛通- 最 高28.38
- 今 開28.34
- 成交量 178.22万股
- 最 低 27.975
- 昨 收 28.21
- 總市值 125.68亿
- 52周最高 31.235
- 市盈率 靜 11.05
- 換手率 0.40%
- 52周最低 24.99
- 委 比 94.14%
- 總股本 4.49亿
- 歷史最高 53.33
- 量 比 1.05
- 振 幅 1.44%
- 歷史最低 24.99
- 每 手 1
- 風險率 1.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
09-19 01:35
Ascendis stock falls 12% amid lowered outlook, royalty deal
Shares of Ascendis (ASND) fell 12% in morning trading Wednesday, the day after the Danish drug developer lowered its revenue outlook and announced it had entered into a royalty funding deal with Royal...
09-04 23:06
Ascendis Pharma GAAP EPS of -€1.91, revenue of €36M; revises FY24 revenue outlook
Ascendis Pharma press release (ASND): Q2 GAAP EPS of -€1.91. Revenue of €36M (-24.0% Y/Y). SKYTROFA Q2 revenue of €26 million – 134% year-over-year volume growth offset by negative adjustment of €27 m...
09-04 13:43
Ascendis and Royalty Pharma enter into $150M royalty funding agreement
Ascendis Pharma (ASND) and Royalty Pharma (NASDAQ:RPRX) said on Tuesday that Ascendis Pharma Bone Diseases, a subsidiary of Ascendis has entered into a $150M royalty funding agreement with Royalty Pha...
09-04 05:17
快讯 | Ascendis Pharma和royalty pharma达成1.5亿美元的版税融资协议
Ascendis Pharma and Royalty Pharma Enter Into $150 Million Royalty Funding Agre...
09-04 05:06
Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A 'Very Overvalued Situation'
Jim Cramer discusses Snowflake, Royalty Pharma, Core Scientific and Ally Financial on "Mad Money Lightning Round."
08-16 21:28
A Look At The Intrinsic Value Of Royalty Pharma Plc (NASDAQ:RPRX)
Key Insights The projected fair value for Royalty Pharma is US$29.52 based on...
08-15 18:14
Cytokinetics cut at Goldman Sachs on diminished strategic interest
Goldman Sachs has lowered its rating on heart drug developer Cytokinetics (NASDAQ:CYTK) to Neutral from Buy, arguing that the strategic interest in the company has diminished while potentially positiv...
08-13 20:52
快讯 | Royalty Pharma PLC：摩根士丹利将目标价从51.00美元下调至50.00美元。
Royalty Pharma PLC : Morgan Stanley Cuts Target Price to $50.00 From $51.00
08-09 21:17
Royalty Pharma shares are trading lower after the company reported worse-than-expected Q2 financial results.
Royalty Pharma shares are trading lower after the company reported worse-than-e...
08-08 22:45
